medigraphic.com

2011, Number 5

Next >>

Rev Med Inst Mex Seguro Soc 2011; 49 (5)

Therapeutic use Hibiscus sabadariffa extract in the treatment of hypercholesterolemia. A randomized clinical trial

Hernández-Pérez F, Herrera-Arellano A

Language: Spanish
References: 30
Page: 469-480
PDF size: 87.84 Kb.


ABSTRACT

Objective: to compare the effectiveness, safety and tolerability of Hibiscus sabadariffa extract (SHE) versus pravastatin in hypercholesterolemia.
Methods: double blind and controlled clinical trial. Men and women with hypercholesterolemia ≥ 220 mg/dL, over 30 years without previous treatment were included. Treatments: Experimental I, SHE standardized 10 mg of anthocyanins, control, 20 mg of pravastatin, Experimental II, extract of H. sabdariffa, standardized to 20 mg of anthocyanins along 12 weeks. SHE Data analysis with Anova and χ2 tests were used.
Results: we included 104 patients, at baseline there were no significant differences in age, weight, BMI, total cholesterol, HDL, LDL, VLDL and triglycerides. At the end of the study, the experimental I reduced triglycerides (p ≤ 0.0001), the control treatment reduced triglycerides, cholesterol total and its fractions (p = 0.02), and finally, the experimental treatment II reduced triglycerides (p = 0.0001). The three treatments showed high percentages (› 96) of safety and tolerability, without showing significant differences (p ≥ 0.57).
Conclusions: the treatments, with 10 and 20 mg of anthocyanins reduce triglycerides. The control treatment showed the greatest effect on lowering total cholesterol and fractions to experimental treatments.


REFERENCES

  1. ACC/AHA. Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28:1328-1428.

  2. Gotto A, Farner J. Factores de riesgo de cardiopatía isquémica. En: Faergeman O. The atherosclerosis epidemic: methodology, nosology, and clinical practice. México: Interamericana McGraw-Hill; 1990. p. 1253-1293.

  3. Faergeman O. The atherosclerosis epidemic: methodology, nosology, and clinical practice. Am J Cardiol 2001;88(2 Suppl 1):4E-7E.

  4. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med 1999;341(4):226-232. Disponible en http://www.nejm.org/doi/pdf/10.1056/NEJM199907223410402

  5. 5 Camacho HR, Corona MI, Vázquez MJ, Martínez RF, Escobedo de la Peña J. Risk factors for ischemic heart disease in Mexico: a case control study. Arch Inst Cardiol Mex 1995;65(4):315-322.

  6. Grupo Cooperativo del Consenso. Primer consenso mexicano sobre los síndromes isquémicos coronarios agudos sin elevación del segmento ST (angina inestable e infarto no Q), Cancún, Quintana Roo 15 y 16 de noviembre, 2001. Arch Cardiol Mex 2002;72(Suppl 2): S5-S44.

  7. Isselbacher K, Braunwald E. Hiperlipoproteinemias y otros trastornos del metabolismo lipídico. En: Kasper, DL, Braunwald E, Fauci AS, Hauser SL, Longo DL Jameson JL, editores. Harrison. Principios de medicina Interna. Décima sexta edición. España: Mc Graw Hill; 2006. p. 2372-2384.

  8. Escobedo de la Peña J, Escamilla CJ, Santos BC. Colesterol sérico y diabetes mellitus: principales factores de riesgo independientes en la mortalidad por cardiopatía isquémica en México Arch Inst Cardiol Mex 1994;64 (2):189-194.

  9. Posadas RC, Sepúlveda J, Tapia CR, et al. Valores de colesterol sérico en la población mexicana. Salud Publica Mex 1992;34(2):157-167.

  10. Verdejo J, Llamas G. Manejo de la ateroesclerosis en la fase crónica. Arch Inst Cardiol Mex 2000;70(1):83-90.

  11. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335(14):1001-1009.

  12. Brewer HB. Hypertriglyceridemy: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999;83(9B):2F-12F.

  13. Kwiterovich P. The metabolic pathways of high density lipoprotein, low density lipoprotein, and triglycerides: A current Review. Am J Cardiol 2000;86(14 A suppl):5L-10L.

  14. Ginsberg HN. Nonpharmacologic management of low levels of high density lipoprotein cholesterol. Am J Cardiol 2000;86(12 Suppl 1):41L-45L.

  15. Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269(23):3015-3023.

  16. Piepho R. The pharmacokinetics and pharmacodynamics of agents proven to rise high-density lipoprotein cholesterol. Am J Cardiol 2000;86(12 A Suppl.):35L-40L.

  17. Hardman J, Limbird L, Molinoff P. Fármacos usados en el tratamiento de hiperlipoproteinemias. En: Goodman GA, Rall TW, Nies AS, Taylor P, editores. Goodman y Gilman. Las bases farmacológicas de la terapéutica. Novena edición. México: Panamericana; 1993. p. 936-959.

  18. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Group. Prevention of cardiovascular event and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349-1357. Disponible en http://www.nejm.org/doi/pdf/10.1056/NEJM199811053391902

  19. Rao P, Seshadri TR. Pigments of the flowers of Hibiscus sabadariffa. Isolation of sabdaretin, a new hydroxiflavone. Proc Indian Acad Sci 1942;16:323-324.

  20. Yamamoto R, Osima Y. Red coloring matter of Hibiscus sabdarifa. A new glucoside Hibiscin. Sci Pap Inst Phys Chem Res 1932;19:134-136.

  21. Chang YC, Huang KX, Huang AC, Ho YC, Wang CJ. Hibiscus anthocyanins-rich extract inhibited LDL oxidation and oxLDL-mediated macrophages apoptosis. Food Chem Toxicol 2006;44(7):1015-1023

  22. Jonadet M, Bastide J, Bastide P, Boyer B, Carnat AP, Lamaison J. In vitro enzyme inhibitory and in vivo cardioprotective activities of hibiscus (Hibiscus sabdariffa L.) J Pharm Belg 1990;45(2):120-124.

  23. Tseng T, Kao E, Chu C, Chou F, Lin Wu H, Wang C. Protective effects of dried flower extracts of Hibiscus sabdariffa L. against oxidative stress in rat primary hepatocytes. Food Chem Toxicol. 1997;35:1159-164.

  24. Frank T, Janssen M, Netzel M, Strass G, Kler A, Kriesl E, et al. Pharmacokinetics of anthocyanidin-3-glycosides following consumption of Hibiscus sabdariffa L. extract. J Clin Pharmacol 2005;45(2):203-210.

  25. Salama R. Ergosterol in Hibiscus sabadariffa seed oil. Planta Med 1979; 36:221-223.

  26. El-Merzabani M, El-Aaser A, Attia MA, El-Duweini A, Ghazal AM. Screening system for Egyptian plants with potential anti-tumor activity. Planta Med 1979;36(2):150-155.

  27. Aquino DY, Nesme AJ, Alvarado GR, Gatica VR. Efecto protector de la Hibiscus sabadariffa (jamaica) en hiperlipidemias. Memorias de la VII Reunión Nacional de Investigación Médica. México: Instituto Mexicano del Seguro Social; 1998. p. 262.

  28. El-Saadany SS., Sitohy MZ., Labib SM, El-Massryda L., Biochemical dynamics and hypocholesterolemic action of Hibiscus sabdariffa (Karkade). Nahrung 1991;35(6): 567-576.

  29. Carvajal ZO, Waliszewski SM, Barradas DM, Orta FZ, Hayward JP, Nolasco HC, et al. The consumption of Hibiscus sabdariffa dried calyx ethanolic extract reduced lipid profile in rats. Plant Foods Hum Nutr 2005;60(4):153-159.

  30. Hirunpanich V, Utaipat A, Morales NP, Bunyapraphatsara N, Sato H, Herunsale A, et al. Hypocholesterolemic and antioxidant effects of aqueous extracts from the dried calyx of Hibiscus sabdariffa in hypercholesterolemic rats. J Ethnopharmacol 2006; 103(2):252-260.




2020     |     www.medigraphic.com